We are (SEBI Regn No. INP100007286) an India focused, public market investment firm (PMS) that aims to generate attractive absolute risk adjusted return
We believe Indian Pharma has multiple tailwinds & exports can grow significantly over next 5 yrs. Multiple winners will emerge, who move up the ladder & gain market share. Our Apr'26 memo captures the same & how we are positioning our portfolio accordingly
https://t.co/N8bwJRbQIk
(1/11) Investing in IPOs is risky and asymmetric. Nearly 80% of the companies listed in the last 15 years have their IRR below 15%. Also, there is material evidence that these companies slow down significantly after 3 years of their listing.
Delighted to share our founder Anubhav’s interview with @livemint. He discusses his outlook for 2026, sectors poised to outperform, earnings expectations, and strategies for navigating high valuations in small caps.
Full article at: https://t.co/lbDBqccxHy
#Investing#Markets
Steep correction in SMID stocks has created select yet highly attractive opportunities for investors. Our founder Sonal shares his perspective on this evolving risk-reward dynamic of the SMID space in Business Standard.
Read the full article at : https://t.co/r2Rqz6BJya
Delighted to share our founder Sonal’s insights in Moneycontrol’s Daily Voice. He outlines a positive outlook for 2026, expecting mid-teen returns, and discusses sectors positioned to deliver strong earnings momentum.
Read the full article: https://t.co/y4fbpiLaDa
Delighted to share our perspective on the Indian auto ancillary sector, featured in Business Standard. Our founder, Anubhav, discusses current trends, emerging opportunities, and the long-term outlook for the industry
Read the full article at:
https://t.co/rWpg8ckSZo
In latest the episode of Moneycontrol's Market Minutes podcast, our founder Sonal shares his insights on RBI’s latest rate cut and what it means for equity markets and investor sentiment.
Check out the podcast at: https://t.co/47DwYndnUo